GNH USA

Europe — EMA

Eylea (Aflibercept)

GNH USA supplies Eylea (Aflibercept), a VEGF inhibitor for neovascular age-related macular degeneration and diabetic macular edema.

Aflibercept

Request sourcing

1
Pack/s

What is Aflibercept?

Aflibercept, the active ingredient in Eylea, is a VEGF inhibitor presented as a 2 mg/0.05 mL intravitreal solution for ophthalmic use. It is used to treat various eye conditions in adults, including neovascular (wet) age-related macular degeneration, diabetic macular edema, and other retinal diseases.

GNH USA supplies Eylea as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide.

What is Aflibercept used for?

Eylea is an anti-angiogenic ophthalmic agent used to treat various retinal diseases by inhibiting abnormal blood vessel growth. It is indicated for the following conditions:

- Neovascular (wet) age-related macular degeneration: Helps stabilize and improve vision loss. - Diabetic macular edema: Reduces macular swelling caused by diabetes. - Macular edema secondary to retinal vein occlusion: Alleviates swelling due to blocked retinal veins. - Myopic choroidal neovascularization: Prevents abnormal blood vessel growth in severe myopia.

What are the side effects of Aflibercept?

Eylea may cause side effects, ranging from mild to serious. Common Side Effects: - Eye pain or redness at the injection site. - Conjunctival hemorrhage (small bleeding spots on the eye). - Increased intraocular pressure. - Floaters or flashes of light.

Serious or Rare Side Effects: - Endophthalmitis (severe eye infection). - Retinal detachment or tears. - Cataracts or lens damage. - Vitreous hemorrhage (bleeding inside the eye). - Increased risk of stroke or heart attack in certain patients.

What precautions apply to Aflibercept?

Eylea should be used with caution, and certain precautions should be observed. Consult a healthcare provider before use. Avoid use in patients with active eye infections. Monitor for signs of increased intraocular pressure. Use with caution in patients with a history of stroke or heart disease. Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

What does Aflibercept interact with?

Eylea may interact with other medications, requiring careful monitoring. Major Interactions (Avoid): - None identified.

Moderate Interactions (Monitor Closely): - Other anti-VEGF therapies: Increased risk of ocular side effects. - Immunosuppressants: May increase infection risk. - Anticoagulants: May increase bleeding risk.

Frequently asked questions

What is Eylea used for?+
Eylea is used to treat several retinal diseases, including neovascular (wet) age-related macular degeneration, diabetic macular edema, macular edema secondary to retinal vein occlusion, and myopic choroidal neovascularization. It helps to stabilize and improve vision by inhibiting abnormal blood vessel growth in the retina.
How does Aflibercept work?+
Aflibercept works by binding to vascular endothelial growth factor (VEGF-A, VEGF-B) and placental growth factor (PlGF), preventing their activation of VEGF receptors. This inhibition blocks pathological angiogenesis, reducing abnormal blood vessel growth and leakage in the retina, which helps to stabilize and improve vision in various retinal diseases.
What is the usual dose of Eylea?+
The usual dose of Eylea is 2 mg (0.05 mL) administered as an intravitreal injection. The dosing regimen is determined by a healthcare provider based on the specific condition being treated and the patient's response to therapy.
Is Eylea safe during pregnancy or breastfeeding?+
The safety of Eylea during pregnancy or breastfeeding has not been established. It should be used with caution in pregnant or breastfeeding women, and only if the potential benefits outweigh the risks. Consult a healthcare provider for personalized advice.
How do I order Eylea from GNH USA?+
To order Eylea from GNH USA, submit an enquiry on the product page at gnh-usa.com with the required quantity. GNH USA supplies hospitals, pharmacies, and procurement teams across international markets and will ask the buyer to confirm trade or institutional credentials. The team will reply with pricing, availability, shipping, and the import paperwork.
How does Eylea compare to other anti-VEGF therapies?+
Eylea is one of several anti-VEGF therapies used to treat retinal diseases. It is distinguished by its dual targeting of VEGF-A, VEGF-B, and PlGF, which may provide broader coverage in inhibiting pathological angiogenesis. The choice between Eylea and other anti-VEGF therapies depends on the specific condition, patient response, and healthcare provider preference.
How should Eylea be stored and handled?+
Eylea should be stored at 2-8°C, kept refrigerated, protected from light, and not frozen or shaken. The unopened vial can be stored at temperatures below 25°C for up to 24 hours if necessary. Always follow the storage instructions provided with the product to ensure its efficacy and safety.
How is Eylea administered?+
Eylea is administered as an intravitreal injection, which is performed by a healthcare provider in a clinical setting. The eye is cleaned with a disinfectant, and a local anesthetic is applied to minimize discomfort during the injection.
What are the most serious risks to watch for with Eylea?+
The most serious risks associated with Eylea include endophthalmitis (severe eye infection), retinal detachment or tears, cataracts or lens damage, vitreous hemorrhage (bleeding inside the eye), and increased risk of stroke or heart attack in certain patients. Patients should be monitored closely for these potential complications.
Who should not use Eylea?+
Eylea should not be used in patients with active eye infections or those who have had a severe allergic reaction to Aflibercept or any of the excipients in the formulation. It should be used with caution in patients with a history of stroke, heart disease, or other conditions that may increase the risk of adverse events.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Aflibercept
Route
Intravitreal Use
Manufacturer
Bayer Ag
Origin
EU

Related products

Eylea 2 mg

Eylea 2 mg

Aflibercept · 2 MG

Eylea
SOLUTION
BAYER INC
CANADA
Eylea 2 mg

Eylea 2 mg

Aflibercept · 2 MG

Eylea
SOLUTION
BAYER INC
CANADA
Yesafili 2 mg

Yesafili 2 mg

Aflibercept · 2 MG

Yesafili
SOLUTION
BIOSIMILAR COLLABORATIONS IRELAND LIMITED
IRELAND
Pavblu 2 mg

Pavblu 2 mg

Aflibercept · 2 MG

Pavblu
SOLUTION
AMGEN CANADA INC
CANADA